Asia-Pacific Viscosupplementation Market Size and Growth Trends - Share Analysis and Forecast Report 2025-2033

Asia-Pacific Viscosupplementation Market Trends & Summary

Asia-Pacific Viscosupplementation Market is expected to reach US$ 3.80 billion by 2033 from US$ 1.60 billion in 2024, with a CAGR of 10.1% from 2025 to 2033. Among the major reasons propelling the market are the rising incidence of osteoporosis and osteoarthritis (OA) as well as consumers' growing preference for minimally invasive non-surgical therapies.

Asia-Pacific Viscosupplementation Market Report by Product (Single Injection, Three Injection, Five Injection), Application (Knee Osteoarthritis, Hip Osteoarthritis, Hand/Wrist Osteoarthritis, Ankle/Foot Osteoarthritis, Others), End User (Hospitals, Orthopedic clinics/Ambulatory Surgical Centers), Countries (China, Japan, India, South Korea, Thailand, Malaysia, Indonesia, Australia, New Zealand, Rest of Asia Pacific) and Company Analysis, 2025-2033

Asia-Pacific Viscosupplementation Industry Overview

Due to the growing incidence of osteoarthritis and the region's aging population, the viscosupplementation market in Asia Pacific is expanding significantly. Because of increased access to healthcare services, increased awareness of joint health, and expanded payment coverage for viscosupplementation procedures, nations like South Korea, China, and Japan are driving this expansion. The market demand is being further stimulated by technological developments in hyaluronic acid (HA) formulations, such as single-injection and longer-lasting treatments. Additionally, viscosupplementation is becoming a more attractive option than surgery because to the need for minimally invasive procedures and outpatient care.

A robust pipeline of new medications and the expansion of both domestic and international pharmaceutical companies are also helping the industry. Frequent product releases, mergers, and strategic alliances increase accessibility and market rivalry. However, obstacles like disparate legal systems, low knowledge in rural regions, and the expensive price of certain viscosupplementation products could prevent wider usage. Despite these obstacles, the Asia Pacific region is still a promising place for viscosupplementation therapy, and over the next ten years, growth will be supported by increased patient education programs and ongoing expenditures in research and development.

The growing number of patients with osteoarthritis and the growing availability of sophisticated and combination solutions are some of the reasons propelling the market's expansion. For example, an article named "Osteoarthritis" from the Centers for Disease Control and Prevention in April 2020 states that approximately 32.5 million Americans suffer from osteoarthritis. In addition, osteoarthritis affects 62% of women. According to a January 2021 article titled "Prevalence of knee osteoarthritis, its determinants, and impact on the quality of life in elderly persons in rural Ballabgarh, Haryana" published by the National Center for Biotechnology Information, 64.3% of the elderly population has knee osteoarthritis, and the quality of life is significantly lower for elderly patients who have the condition. Moreover, another risk factor for orthopedic disorders is obesity.

For example, 'Prevalence of Obesity in India and its Neurological Implications: A Multifactor Analysis of a Nationwide Cross-Sectional Study,' published in 2021 by the National Center for Biotechnology Information, states that 40.3% of Indians are obese. Furthermore, South India has the highest prevalence rate (46.51%), while East India has the lowest (32.96%). As a result, the growing number of patients suffering from osteoarthritis is probably going to raise demand for viscosupplementation methods, which promote joint lubrication and lessen joint discomfort. This will boost market growth over the projection period.

Growth Drivers for the Asia Pacific Viscosupplementation Market

Rising Prevalence of Osteoarthritis

One major factor propelling the growth of the Asia Pacific viscosupplementation market is the increasing incidence of osteoarthritis. Joint-related illnesses are becoming more common as the region's population ages quickly, especially in nations like China, India, and Japan. Younger populations are also experiencing osteoarthritis at an earlier age because to sedentary lifestyles, obesity, and bad eating habits. There is a significant need for efficient, non-surgical treatment solutions as a result of the rising illness load. A less intrusive option to surgery is viscosupplementation, which involves injecting hyaluronic acid into the joint to reduce discomfort and increase mobility. It is becoming more and more well-liked by patients and medical professionals because to its capacity to postpone or lessen the necessity for joint replacement operations.

Growing Preference for Minimally Invasive Treatments

The Asia Pacific region's need for viscosupplementation is being greatly increased by patients' increasing choice for minimally invasive procedures. Vscosupplementation has been a popular choice as patients look for surgical alternatives that have less side effects and faster recovery periods. Without the risks of surgery, this method, which includes injecting hyaluronic acid into the joint, provides improved mobility and good pain relief. Because it may be done as an outpatient procedure, it is more practical and economical for patients as well as healthcare systems. The market is expanding as more people choose viscosupplementation as a first-line treatment for osteoarthritis and joint discomfort due to increased awareness, easier access to orthopedic care, and improvements in injection procedures.

Technological Advancements in Hyaluronic Acid (HA) Products

Hyaluronic acid (HA) product technological developments are a major factor propelling the Asia Pacific viscosupplementation industry. Treatment effectiveness and patient convenience are being greatly improved by innovations including extended-release formulations and single-injection regimens. By lowering the number of necessary clinic visits, these next-generation HA medicines increase patient compliance and lessen the burden of therapy. Additionally, longer-lasting formulas offer consistent joint pain alleviation, improving overall patient satisfaction and treatment results. These advancements provide doctors more freedom in treating osteoarthritis and customizing treatment regimens for each patient. More sophisticated, patient-friendly viscosupplementation solutions are anticipated to hit the market as R&D expenditures rise, hastening acceptance in the region's various healthcare settings.

Challenges in the Asia Pacific Viscosupplementation Market

High Cost of Treatment

One major obstacle to the broad adoption of viscosupplementation therapy in the Asia Pacific area is still its high cost. Advanced formulations of hyaluronic acid (HA), especially those that are single-injection or extended-release, are frequently more expensive. These treatments are less accessible to middle- and lower-class citizens in many nations since they are not entirely covered by insurance companies or public healthcare systems. Because of this, a lot of people choose less expensive but less effective options like corticosteroid injections or oral medicines. In rural and semi-urban areas, where paying for healthcare out of pocket is typical, this expense issue is exacerbated. The entire market potential of viscosupplementation in the area might go unrealized until price becomes more competitive or reimbursement policies are improved.

Limited Awareness in Rural Areas

The Asia Pacific viscosupplementation market's expansion is severely hampered by low awareness in rural and underdeveloped areas. Many of these areas still lack basic pain alleviation understanding about osteoarthritis care choices. Unaware that therapies like viscosupplementation can provide longer-term alleviation and increased mobility, patients frequently turn to conventional treatments or over-the-counter drugs. Furthermore, underdiagnosis and a lack of available treatments may result from healthcare providers in these areas not having access to resources or updated training. This disparity is made worse by the absence of infrastructure and focused education initiatives to enable advanced joint care. To increase access and guarantee a wider uptake of viscosupplementation throughout the region, it is imperative to close this awareness gap.

China Viscosupplementation Market

A growing senior population and rising awareness of non-surgical osteoarthritis therapies are driving China's viscosupplementation market's steady expansion. Viscosupplementation has grown in popularity among consumers and medical experts as more people look for minimally invasive ways to treat joint discomfort and increase mobility. The treatment is a desirable alternative to joint replacement surgery since it can postpone or lessen the need for it, particularly in urban areas where access to cutting-edge medical care is easier to come by.

Furthermore, improvements in hyaluronic acid formulations, such as single-injection treatments, are improving patient outcomes and convenience. But obstacles including inadequate insurance coverage, exorbitant medical expenses, and awareness gaps between urban and rural areas still hinder wider market adoption nationwide.

Japan Viscosupplementation Market

Japan's aging population and rising osteoarthritis prevalence are driving the country's viscosupplementation market's steady expansion. The need for non-surgical treatments like viscosupplementation is growing as more than 60% of adults have radiographic knee osteoarthritis, with 26% of those patients having symptomatic knee osteoarthritis.

Chugai Pharmaceutical, Seikagaku, Bioventus, Fidia Farmaceutici, Sanofi, Bloomage Freda Biopharm, Zimmer Biomet, and Ferring Pharmaceuticals are some of the top companies in the Japanese market. Since its 1987 launch, Seikagaku's ARTZ has maintained a strong reputation and a substantial market share in Japan.

Notwithstanding these developments, issues like exorbitant medical expenses and restricted insurance coverage still exist. Furthermore, the introduction of novel viscosupplementation products may be slowed down by Japan's strict regulatory clearance procedures. For the Japanese viscosupplementation market to reach its full potential, these obstacles must be removed.

India Viscosupplementation Market

Because osteoarthritis is becoming more common in India, especially among the elderly population, the market for viscosupplementation is expanding. Since osteoarthritis of the knee is one of the most common joint conditions, there is a growing need for non-surgical therapies like viscosupplementation. By injecting hyaluronic acid into the joint, this therapy can reduce pain and increase mobility, making it a viable substitute for more conventional therapies like joint replacement surgery or opioids.

With a prevalence of 22% to 39%, osteoarthritis is the second most prevalent rheumatological condition in India. One of the main causes of decreased mobility, particularly in women over 65, is osteoarthritis of the knee. Notwithstanding the rising desire for non-surgical procedures like viscosupplementation, obstacles including exorbitant treatment expenses and restricted insurance coverage still hinder the country's overall market penetration. For the Indian viscosupplementation market to reach its full potential, these obstacles must be removed.

South Korea Viscosupplementation Market

The market for viscosupplementation in South Korea is expanding significantly due to the rising incidence of osteoarthritis and the desire for non-surgical remedies. The need for efficient joint treatments has increased as a result of the nation's aging population and high prevalence of osteoarthritis in the knee. The healthcare system's emphasis on affordable and patient-friendly therapies is in line with the minimally invasive alternatives to standard surgical choices provided by viscosupplementation, especially hyaluronic acid injections. ​

To meet the varied demands and preferences of patients, the market is distinguished by a wide range of product offerings, such as single, three, and five-injection regimens. The main locations for these surgeries are hospitals and orthopedic clinics, which are aided by South Korea's sophisticated healthcare system. However, there are still issues that could prevent wider adoption, like exorbitant treatment costs and little insurance coverage. By addressing these obstacles with changes to policy and greater awareness, viscosupplementation therapy may become even more accessible and expand throughout the nation.

Asia-Pacific Viscosupplementation Market Segments

Product –Market breakup in 3 viewpoints:

• Single Injection
• Three Injection
• Five Injection                              

Application –Market breakup in 5 viewpoints:

• Knee Osteoarthritis
• Hip Osteoarthritis
• Hand/Wrist Osteoarthritis
• Ankle/Foot Osteoarthritis
• Others

End User –Market breakup in 2 viewpoints:

• Hospitals
• Orthopedic clinics/Ambulatory Surgical Centers            

Country –Market breakup in 10 viewpoints:

• China
• Japan
• India
• South Korea
• Thailand
• Malaysia
• Indonesia
• Australia
• New Zealand
• Rest of Asia Pacific

All the Key players have been covered from 4 Viewpoints:

• Overview
• Key Persons
• Recent Developments
• Revenue

Company Analysis:

1. Anika Therapeutics, Inc.
2. Zimmer Biomet
3. Smith & Nephew PLC
4. F.Hoffmann-La Roche Ltd.
5. Sanofi
6. Chugai Pharmaceutical Co.
7. Lifecore Biomedical
8. LG Life Sciences Ltd.

Report Details: